Terbinafine 250 mg tablets are oral antifungal medications used primarily to treat systemic and superficial fungal infections. It belongs to the class of allylamine antifungals, which work by inhibiting the enzyme squalene epoxidase, involved in the synthesis of ergosterol, a key component of fungal cell membranes. This prevents fungal growth and reproduction.
Usual Dosage: 250 mg once daily.
o For Onychomycosis: 250 mg daily for 6-12 weeks (depending on the infection and the site).
o For other Tinea infections: 250 mg daily for 2-6 weeks depending on the severity and type of infection.
Instructions: Take the tablet by mouth with or without food. Swallow the tablet whole with a glass of water. Avoid crushing or chewing the tablet.
Duration: The duration of therapy depends on the specific infection being treated. Treatment for nail infections usually takes longer than for skin infections.
Liver Disease: Terbinafine can cause liver toxicity. It should be used with caution in individuals with liver disorders, and liver function tests should be monitored during treatment.
Kidney Disease: Caution is advised in patients with kidney problems, as dose adjustments may be necessary.
Pregnancy: Not recommended during pregnancy unless clearly needed, as it may pose risks to the fetus. Always consult your doctor if pregnant or planning to become pregnant.
Breastfeeding: Terbinafine is excreted in breast milk, so it is generally advised to avoid its use while breastfeeding, unless the benefit outweighs the risk.
Allergic Reactions: Discontinue use if signs of an allergic reaction appear, such as rash, itching, or swelling.
Drug Interactions: Terbinafine can interact with other medications (e.g., rifampin, cyclosporine), so inform your doctor of all current medications to avoid potential interactions.
Side Effects: Common side effects include gastrointestinal symptoms (nausea, diarrhea), headache, and dizziness. Rare but serious side effects include liver damage (e.g., jaundice, dark urine), skin reactions, and taste disturbances.